Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis

Basit Öğe Kaydı
dc.authoridŞenol Kobak / 0000-0001-8270-640X
dc.authorscopusidŞenol Kobak / 12782228700
dc.authorwosidŞenol Kobak / AAO-2482-2020
dc.contributor.authorKobak, Şenol
dc.contributor.authorSemiz, Hüseyin
dc.date.accessioned2020-08-30T20:06:19Z
dc.date.available2020-08-30T20:06:19Z
dc.date.issued2020
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionKOBAK, SENOL/0000-0001-8270-640Xen_US
dc.descriptionKobak, Şenol (isu author)
dc.description.abstractBackground : Psoriatic Arthritis (PsA) is a chronic inflammatory disease that may affect different joints. Sarcoidosis is a Th-1 cell -related chronic granulomatous disease characterized by non -caseating granuloma formation. The coexistence of both the diseases is a rare entity. Usteki- numab, an IL12 / 23 inhibitor, has shown efficacy and safety in the treatment of PsA. Objective : This study presents a case with ustekinumab-induced sarcoidosis in a patient with PsA. Case Report : A 52 years old female patient with complaints of pain and swelling of the wrists, MCP, PIP and DIP joints and skin lesions was referred to our Rheumatology clinic. On her medical history, she had been under follow up for 5 years with the diagnosis of psoriasis and one year ago, she started to receive ustekinumab prescribed by a dermatologist. On physical examination, she had psori- asis skin lesions and arthritis of both wrists, MCP, PIP, DIP joints. Bilateral hilar lymphadenopathies were detected in the chest X-ray and thorax computed tomography. In laboratory tests, acute phase re- actants and serum angiotensin-converting enzyme levels were high. Endobronchial ultrasonography biopsy was performed and non -caseating granuloma consistent with sarcoidosis was reported. Usteki- numab was discontinued, methotrexate and low -dose corticosteroid were started. The patient was clin- ically stable in the 6 th month of the treatment and the findings were regressed. Conclusion : Sarcoidosis development appears to be a new paradoxical effect of ustekinumab thera- py, being another biological agent.en_US
dc.identifier.citationKobak, S., & Semiz, H. (2020). Ustekinumab-induced Sarcoidosis in a Patient with Psoriatic Arthritis. CURRENT DRUG SAFETY, 15(2), 163–166. https://doi.org/10.2174/1574886315666200316113312en_US
dc.identifier.doi10.2174/1574886315666200316113312en_US
dc.identifier.endpage166en_US
dc.identifier.issn1574-8863en_US
dc.identifier.issn2212-3911en_US
dc.identifier.issue2en_US
dc.identifier.pmid32178618en_US
dc.identifier.scopus2-s2.0-85086398101en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage163en_US
dc.identifier.urihttps://doi.org/10.2174/1574886315666200316113312
dc.identifier.urihttps://hdl.handle.net/20.500.12713/468
dc.identifier.volume15en_US
dc.identifier.wosWOS:000545985200005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKobak, Şenolen_US
dc.language.isoenen_US
dc.publisherBentham Science Publen_US
dc.relation.ispartofCurrent Drug Safetyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSarcoidosisen_US
dc.subjectUstekinumaben_US
dc.subjectPsoriatic Arthritisen_US
dc.subjectIl12en_US
dc.subject23 Inhibitoren_US
dc.subjectDip Jointsen_US
dc.subjectMcp Jointsen_US
dc.titleUstekinumab-induced sarcoidosis in a patient with psoriatic arthritisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
321.pdf
Boyut:
4.96 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu